IBS Treatment Market is expected to grow at a CAGR over 13.8% from 2022 to 2030

Pune, India, January 2022 /MRFR Press Release/- Market Research Future has a cooked research report on the Americas IBS treatment market.

Market Highlights:

There are wide market for irritable bowel syndrome treatment in the Americas owing to increasing prevalence of patients suffering with anxiety, people feel the effects of stress in many way and one of the common symptom is  irritable bowel syndrome . Anxiety can worsen symptoms of abdominal cramps and pain and make one  feel sick in the stomach. Rising prevalence of population suffering with anxiety are the leading causes for the growth of Americas IBS market. According to updated report by Anxiety and Depression Association of America, in 2017, approximately 30 % of the adult population in North America has anxiety disorder issues. Presence of huge patient population with anxiety, have increased the chance of occurrence IBS in this region. Thus, big players are focusing on better treatment option in order to serve the patient suffering from irritable bowel syndrome .

The Americas IBS treatment market is anticipated to reach USD 3952.8 Million by 2030 at 13.8% CAGR during the forecast period 2022-2030.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of IBS Treatment Market Research Report

Taste the market data and market information presented through more than 40 market data tables and figures spread over 69 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “IBS treatment market research report– Americas forecast till 2030.”

Major Players in the IBS treatment Market

Some of the key players in this market are Allergan Plc (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma Inc. (Japan), Valeant Pharmaceuticals (Canada), Abbott Laboratories (U.S.), Synergy Pharmaceuticals, Inc. (U.S.), Ardelyx, Inc. (U.S.), Nestle (Switzerland), Sebela Pharmaceuticals (Ireland), Probi (Sweden), Alfasigma USA, Inc. (Italy), RedHill Biopharma Ltd. (Israel), AstraZeneca (U.K), Ipsen (France), Novartis AG (Switzerland), Takeda Pharmaceutical Company Ltd (Japan), Synthetic Biologics, Inc. (U.S.), Protagonist Therapeutics Inc. (U.S.), Pfizer Inc (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Innovate Biopharmaceuticals (U.S.), 4D pharma plc (U.K).

Considering the Americas irritable bowel syndrome treatment market, there are two main regions: North America, and South America. North America consists of United States and Canada. United States holds largest market share due to the increasing burden of diseases, the share for functional gastrointestinal disorder is also increasing. According to a report published by the International Foundation for Functional Gastrointestinal Disorders, in 2016, functional gastrointestinal (GI) and motility disorders are the most common GI disorders which accounted for 1 in 4 people or more in the United States.

Canada is the second-largest market for irritable bowel syndrome owing to presence of patient population. Moreover, Increasing investment by organizations in the field of irritable bowel syndrome serves as a significant driver for the Canada, the market of IBS is expected to grow at a CAGR of 6.1%.

North America holds the major share of the market whereas, South America shows the fastest growth across the Americas region owing to the presence of an opportunity for the development of the market.

Segmentation

The Americas IBS treatment market is segmented on the basis of types, drugs type, and end user. On the basis the types, it is segmented into IBS-D, IBS-C, IBS-M. On the basis of the drug type, it is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others. On the basis of the end users, it is segmented into hospitals, clinics, and research laboratories.